ID: ALA5208259

Max Phase: Preclinical

Molecular Formula: C33H40F2N6O8S

Molecular Weight: 718.78

Representations

Canonical SMILES:  COC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](OC)[C@H](n3cc(-c4cccc(F)c4)nn3)[C@H]2OC)[C@H](OC)[C@@H](n2cc(-c3cccc(F)c3)nn2)[C@H]1OC

Standard InChI:  InChI=1S/C33H40F2N6O8S/c1-43-17-25-29(45-3)27(41-15-23(37-39-41)19-9-7-11-21(35)13-19)31(47-5)33(49-25)50-32-30(46-4)26(28(44-2)24(16-42)48-32)40-14-22(36-38-40)18-8-6-10-20(34)12-18/h6-15,24-33,42H,16-17H2,1-5H3/t24-,25-,26+,27+,28+,29+,30-,31-,32+,33+/m1/s1

Standard InChI Key:  FMIROIJNGHURPL-XCXSCKOOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 718.78

Molecular Weight (Monoisotopic): 718.2596

AlogP: 3.15

#Rotatable Bonds: 13

Polar Surface Area: 146.26

Molecular Species: NEUTRAL

HBA: 15

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 14

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 0.05

CX LogP: 4.26

CX LogD: 4.26

Aromatic Rings: 4

Heavy Atoms: 50

QED Weighted: 0.22

Np Likeness Score: -0.12

References

1. Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S..  (2022)  Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,  65  (19.0): [PMID:36154172] [10.1021/acs.jmedchem.2c00660]

Source

Source(1):

• Scientific Literature